TY - JOUR T1 - Efficient maternofetal transplacental transfer of anti- SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination JF - medRxiv DO - 10.1101/2021.03.11.21253352 SP - 2021.03.11.21253352 AU - Amihai Rottenstreich AU - Gila Zarbiv AU - Esther Oiknine-Djian AU - Roy Zigron AU - Dana G. Wolf AU - Shay Porat Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253352.abstract N2 - Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy and early infancy can result in severe disease. Evaluating the serologic response after maternal vaccination during pregnancy and subsequent transplacental antibody transfer has important implications for maternal care and vaccination strategies.Objective To assess maternal and neonatal SARS-CoV-2 antibody levels after antenatal mRNA vaccination.Design, Setting, and Participants This study took place at Hadassah Medical Center in Jerusalem, Israel in February 2021. Maternal and cord blood sera were collected for antibody measurement from mother/newborn dyads following antenatal vaccination.Exposure SARS-CoV-2 BNT162b2 mRNA vaccination.Main outcome and measures Spike protein (S) and receptor binding domain (RBD) - specific, IgG levels were evaluated in maternal and cord blood sera.Results The study cohort consisted of 20 parturients, with a median maternal age of 32 y ears and a median gestational age of 393/7 weeks at the time of delivery. The median time lapsed from the first and second doses of vaccine administration until delivery was 33 [IQR 30-37] and 11 [IQR 9-15] days, respectively. Of the 20 dyads, all women an d infants were positive for anti S- and anti-RBD-specific IgG. Anti-S and anti-RBD-specific IgG levels in maternal sera were positively correlated to their respective concentrations in cord blood (ρs= 0.72; P<0.001 and ρs= 0.72; P <0.001, respectively). Anti-S and anti-RBD-specific IgG titers in cord blood were directly correlated with time lapsed since the administration of the first vaccine dose (ρs= 0.71; P =0.001 and ρs= 0.63; P=0.004, respectively).Conclusion and Relevance In this study, SARS-CoV-2 mRNA vaccine administered during pregnancy induced adequate maternal serologic response with subsequent efficient transplacental transfer. Our findings highlight that vaccination of pregnant women may provide maternal and neonatal protection from SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trialFunding StatementNo external funding was used for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of the Hadassah Medical Center approved this study (HMO-0064-21).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors, upon reasonable request. ER -